Your browser doesn't support javascript.
loading
Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?
Lee, H; Duggan, P; Neri, P; Tay, J; Bahlis, N J; Jimenez-Zepeda, V H.
  • Lee H; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Duggan P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Neri P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Tay J; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Bahlis NJ; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Jimenez-Zepeda VH; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Bone Marrow Transplant ; 52(6): 915-917, 2017 06.
Article en En | MEDLINE | ID: mdl-28287637
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre / Citometría de Flujo / Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre / Citometría de Flujo / Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article